Srinivas Nuggehally R
Suramus Biopharm, Integrated Drug Development, J.P. Nagar I phase, Bangalore 560 025, India.
Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):147-50. doi: 10.1007/BF03191165.
Recent evidences suggest that genetic CYP2C19 polymorphism plays a role in the development of treatment resistance for clopidogrel's antiplatelet therapy. This short communication puts forward some strategies that could be potentially used to overcome the genetic polymorphism associated hurdles. While there is some established evidence for an induction strategy and design of chemical structure, the proposed dosing input strategy is speculative in nature. Such thought process and novel explorations are important for delivering medicines in genetically and ethnically diverse populations.
近期证据表明，细胞色素P450 2C19（CYP2C19）基因多态性在氯吡格雷抗血小板治疗耐药性的发生中起作用。本简短通讯提出了一些可能用于克服与基因多态性相关障碍的策略。虽然诱导策略和化学结构设计有一些已确立的证据，但所提出的给药输入策略本质上是推测性的。这种思维过程和新颖的探索对于在基因和种族多样化的人群中提供药物很重要。
